More Information

Sandra E. Reznik

Pharmaceutical Sciences
After graduating from Harvard, Dr. Reznik entered the Medical Scientist Training Program at the Mount Sinai School of Medicine, New York, NY in 1984. Under the direction of Dr. Marian Orlowski, who was nominated for the Nobel Prize in 2004, Dr. Reznik characterized the novel neuropeptide synthesizing enzyme Endopeptidase 24.15, aka thimet oligopeptidase, one of several important processing enzymes discovered by Dr. Orlowski. After obtaining her M.D. and Ph.D. degrees from Mount Sinai, she completed her residency in Anatomic Pathology at New York Hospital/Cornell University Medical College in 1994 and then two fellowships at the Montefiore Medical Center/Albert Einstein College of Medicine from 1996 to 1998. During her second fellowship year at Einstein, she collaborated with Dr. Lloyd Fricker and studied Carboxypeptidase Z (CPZ), a novel processing enzyme highly expressed in the placenta. She received a National Institutes of Health Mentored Clinical Scientist Development Award (K08) in 1998 and remained at Einstein as an attending physician until 2004, where she worked on several peptide processing enzymes, while also practicing perinatal pathology. The work supported by the K08 resulted in the characterization of CPZ and its expression throughout development as well as the identification of endothelin-1 (ET-1) as an important mediator in infection-associated preterm birth. Dr. Reznik accepted a position as Associate Professor at St. John’s University in 2004. Since her arrival at St. John’s, she has focused on reproductive disorders, particularly preterm birth (PTB). Dr. Reznik has established ET-1 and its downstream mediators as potential pharmacotherapeutic targets for inflammation-associated PTB. She has helped elucidate the role of matrix metalloproteases in the premature parturition cascade. In addition, she has very recently shown that inhibition of sphingosine kinase, which is activated by ET-1, represents a new approach for the prevention of preterm labor and delivery. Finally, she has shown that dimethylacetamide, a common solvent, regulates the pro-inflammatory response associated with endotoxin and prevents PTB. Dr. Reznik has published 40 manuscripts, been an invited speaker at international conferences, served on the NICHD Pregnancy and Neonatology (PN) study section and was an organizer of the 2014 American Society of Reproductive Immunology Conference. She has taught over ten different courses, including a graduate class in reproductive pharmacology. Dr. Reznik has a national reputation as a perinatal pathologist, and is often called upon to serve as an expert witness in obstetrical medico-legal cases.

Research Interests

Investigation of the Anti-Inflammatory and Potential Anti-Tocolytic Activities of N,N-Dimethylacetamide Related Compounds Using In Vitro and Ex Vivo Models

Courses Taught


Select Publications

Journal Articles

Reznik, S. E. (2015). BQ-123 Prevents LPS-Induced Preterm Birth Via the Induction of Uterine and Placental IL-10.. Tox App Pharm.

Reznik, S. E. (2014). Increased Placental Trophoblast Inclusions in Placenta Accreta.. Placenta 35.

Reznik, S. E. (2014). Use of the Mouse Ear Vesicant Model to Evaluate the Effectiveness of Ebselen as a Countermeasure to the Nitrogen Mustard Mechlorethamine.. J App Tox 34.

Reznik, S. E. (2013). A Novel Putative Target for the Prevention of Infection-Triggered Preterm Birth.. Obstet Gynecol Internat.

Reznik, S. E. (2012). A Novel Endothelin Receptor Antagonist Prevents Cerebral Microvascular Hemorrhage When Used in Conjunction with an Anti-malarial Agent in Plasmodium berghei ANKA-infected Mice.. Life Sci.

Reznik, S. E. (2012). Altered Regulation of Akt Signaling with Murine Cerebral Malaria, Effects on Long-term Neuro-cognitive Function, Restoration with Lithium Treatment.. PLoS One 7.

Reznik, S. E. (2010). “Plan B:” How It Works. Science Shows It Is Not An Abortifacient.. Health Prog 91.

Reznik, S. E. (2010). Blockade of Endothelin-1 With a Novel Series of 1,3,6-Trisubstituted-2-carboxy-quinol-4-one’s Controls Infection-Associated Preterm Birth. Am J Path 177.

Reznik, S. E. (2010). Endothelin-1 and Matrix Metalloproteinase-1 Function in the Same Molecular Pathway in Infection-Associated Preterm Birth. Molec Med 16.

Reznik, S. E. (2010). Persistent Cognitive and Motor Deficits After Successful Antimalarial Treatment in Murine Cerebral Malaria. Microbes Infect 12.

Reznik, S. E. (2010). Synthesis and Pharmacological Activity of 1,3,6-Trisubstituted-4-Oxo-1,4-Dihydroquinoline-2-Carboxylic Acids as Selective ETA Antagonists. Bioorg Med Chem Lett 20.

Reznik, S. E. (2010). The Matrix Metalloproteases and Endothelin-1 in Preterm Birth.. Obstet Gynecol Internat.

Reznik, S. E. (2008). Expression of Keratin 8 and TRAIL in Down Syndrome Placentas. Placenta 29.

Reznik, S. E. (2008). Phosphoramidon, an Endothelin-Converting Enzyme Inhibitor, Attenuates Lipopolysaccharide-Induced Acute Lung Injury.. Exper Lung Res.

Reznik, S. E. (2008). Placental Matrix Metalloproteinase-1 Is Up-Regulated in Labor.. Reprod Sci.

Reznik, S. E. (2007). The Effect of a Matrix Metalloproteinase Inhibitor on Inflammation-Mediated Preterm Delivery.. Am J Obstet Gynecol.

Reznik, S. E. (2004). The Effect of Phosphoramidon on Inflammation-Mediated Preterm Delivery in a Mouse Model. Am J Obstet Gynecol.

Reznik, S. E. (2001). Carboxypeptidases from A to Z: Implications in Embryonic Development and Wnt Binding. Cell Mol Life Sci 58.


Pekson, R., Poltoratsky, V., Gorasiya, S., Sundaram, S., Ashby, C. R., Vancurova, I., and Reznik, S. E. (2016). N,N-Dimethylacetamide Significantly Attenuates LPS- and TNFα-Induced Proinflammatory Responses Via Inhibition of the Nuclear Factor Kappa B Pathway. Molecular Medicine. vol. 22, pp. 747-758.

preterm birth